Intrommune Therapeutics

Intrommune Therapeutics

Biotechnology, 20 W 125th St Apt 1, City, New York, 10027, United States, 1-10 Employees

intrommune.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 64********

Who is INTROMMUNE THERAPEUTICS

Intrommune Therapeutics, Inc. is a biotechnology company located in New York, NY. Intrommune is developing food allergy immunotherapies that are delivered while you brush your teeth, a li...

Read More

map
  • 20 W 125th St Apt 1, New York City, New York, 10027, United States Headquarters: 20 W 125th St Apt 1, New York City, New York, 10027, United States
  • 2015 Date Founded: 2015
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 5122

checked-icon Does something look wrong? Fix it. | View contact records from INTROMMUNE THERAPEUTICS

Intrommune Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Intrommune Therapeutics

Answer: Intrommune Therapeutics's headquarters are located at 20 W 125th St Apt 1, City, New York, 10027, United States

Answer: Intrommune Therapeutics's phone number is 64********

Answer: Intrommune Therapeutics's official website is https://intrommune.com

Answer: Intrommune Therapeutics's revenue is $1 Million to $5 Million

Answer: Intrommune Therapeutics's SIC: 5122

Answer: Intrommune Therapeutics has 1-10 employees

Answer: Intrommune Therapeutics is in Biotechnology

Answer: Intrommune Therapeutics contact info: Phone number: 64******** Website: https://intrommune.com

Answer: Intrommune Therapeutics, Inc. is a biotechnology company located in New York, NY. Intrommune is developing food allergy immunotherapies that are delivered while you brush your teeth, a lifelong habit that is ingrained in most people and ensures daily use of our product. Intrommune's elegant new treatment platform for food allergies is expected to be safe, effective and convenient. Intrommunes first product is a therapy for patients who suffer from peanut allergy. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 32 million people in the U.S., who suffer from this life-altering condition.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access